| Literature DB >> 33118725 |
Dinçer Uysal1, Fatih Aksoy2, Erdogan Ibrişim1.
Abstract
OBJECTIVE: The aim of this study was to evaluate the value of CHA2DS2-VASc and Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) risk scores for prediction of postoperative atrial fibrillation (AF) development in patients undergoing coronary artery bypass grafting (CABG) operation.Entities:
Keywords: Anticoagulants; Atrial Fibrilation; Coronary Artery Bypass; Drainage; Heart Atria; Logistic Models; Postoperative Period
Year: 2020 PMID: 33118725 PMCID: PMC7598961 DOI: 10.21470/1678-9741-2019-0274
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Demographic and clinical characteristics of patients with and without atrial fibrillation (AF).
| Without AF (n = 260) | With AF (n = 110) | ||
|---|---|---|---|
| Age (years) | 59.8±12 | 68.1±8.4 | < 0.001 |
| Body mass index | 29.0±5.3 | 28.0±4.5 | 0.114 |
| Female gender (n, %) | 82 (31.5) | 24 (21.8) | 0.03 |
| Diabetes mellitus (n, %) | 108 (41.5) | 62 (56.4) | 0.006 |
| Hypertension (n, %) | 184 (70.8) | 100 (90.8) | < 0.001 |
| Congestive heart failure (n, %) | 12 (4.7) | 20. (18.9) | < 0.001 |
| Peripheral vascular disease (n, %) | 70(26.9) | 46(41.8) | 0.004 |
| History of CVA (n, %) | 36 (13.8) | 24 (21.8) | 0.04 |
| Ejection fraction (%) | 56.5±9.4 | 49.2±11.6 | < 0.001 |
| Left atrial diameter (mm) | 39.1±6.1 | 38.9±7.4 | 0.816 |
| LVEDD (mm) | 47.2±5.4 | 46.6±5.0 | 0.296 |
| LVESD (mm) | 29.6±6.8 | 31.3±5.7 | 0.026 |
| IVSD (mm) | 12.0±3.2 | 12.5±2.8 | 0.175 |
| PWD (mm) | 11.1±2.2 | 11.2±1.0 | 0.835 |
| Aortic diameter (mm) | 26.8±3.6 | 26.6±3.1 | 0.580 |
| Total cholesterol (mg/dl) | 201.2±41.3 | 196.9±39.4 | 0.412 |
| HDL cholesterol (mg/dl) | 41±10 | 42±9.8 | 0.713 |
| LDL cholesterol (mg/dl) | 126±40 | 125±34 | 0.915 |
| Triglycerides (mg/dl) | 160±106 | 142±49 | 0.209 |
| Creatinine (mg/dl) | 1.0±0.3 | 1.1±0.4 | 0.161 |
| ALT (U/L) | 22.2±12.2 | 27.5±29.8 | 0.015 |
| AST (U/L) | 31.1±23.6 | 33.0±22.7 | 0.489 |
| Glucose (mg/dl) | 142.5±67 | 198.6±119.9 | < 0.001 |
| CHA2DS2VASc score | 2.2±1.4 | 3.1±1.9 | < 0.001 |
| ATRIA risk score | 1.9±2.4 | 3.4±2.5 | < 0.001 |
Data presented as mean ± standard deviation or number (%) of the patients. CHA2DS2-VASc score stands for congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, previous stroke, vascular disease, age 65 to 74 years, and female gender.
ALT=alanine aminotransferase; AST=aspartate aminotransferase; ATRIA=Anticoagulation and Risk Factors in Atrial Fibrillation; CVA=cerebrovascular accident; HDL=high-density lipoprotein; IVSD=interventricular septum diameter; LDL=low-density lipoprotein; LVEDD=left ventricular end-diastolic diameter; LVESD=left ventricular end-systolic diameter; PWD=posterior wall diameter
Operative and postoperative parameters of the groups.
| Without AF (n = 260) | With AF (n = 110) | ||
|---|---|---|---|
| Cardiopulmonary bypass time (min) | 78.8±27.3 | 86.8±39.6 | 0.02 |
| Clamp time (min) | 47.6±15.4 | 47.0±16.4 | 0.766 |
| 24-hour drainage (ml) | 276.5±137 | 344.5±239 | 0.001 |
| 48-hour drainage (ml) | 145.3±82 | 162.7±71.1 | 0.05 |
| Duration of the hospitalization at the intensive care unit (days) | 2.1±0.4 | 2.6±1.4 | < 0.001 |
| Bypass number (n) | 2.4±2 | 2.4±0.7 | 0.806 |
| Reoperation due to hemorrhage (n, %) | 4 (1.5) | 2 (1.8) | 0.575 |
| Intraoperative mortality (n, %) | - | - | |
| In-hospital mortality (n, %) | 8 (3.1) | 4 (3.6) | 0.500 |
AF=atrial fibrillation
Univariate regression analysis of study variables.
| Odds ratio | Confidence interval | ||
|---|---|---|---|
| CHA2DS2-VASc risk score | 1.38 | 1.21-1.59 | < 0.001 |
| ATRIA risk score | 1.24 | 1.14-1.36 | < 0.001 |
| Fasting glucose level | 1.007 | 1.004-1.009 | < 0.001 |
| Age | 1.08 | 1.05-1.11 | < 0.001 |
| Male gender | 1.65 | 0.97-2.78 | 0.06 |
| ALT level | 1.014 | 1.00-1.02 | 0.03 |
| 24-hour drainage | 1.002 | 1.001-1.003 | 0.001 |
| 48-hour drainage | 1.003 | 1.000-1.005 | 0.056 |
| Left ventricular ejection fraction | 0.93 | 0.91-0.96 | < 0.001 |
| Cardiopulmonary bypass time | 1.008 | 1.001-1.015 | 0.03 |
CHA2DS2-VASc stands for congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, previous stroke, vascular disease, age 65 to 74 years, and female gender.
ALT=alanine aminotransferase; ATRIA=Anticoagulation and Risk Factors in Atrial Fibrillation
Multivariate regression analysis of study variables.
| Model 1 | Model 2 | |||||
|---|---|---|---|---|---|---|
| Odds ratio | Confidence | Odds ratio | Confidence | |||
| 24-hour drainage | 1.002 | 1.001-1.004 | 0.002 | 1.002 | 1.001-1.004 | < 0.001 |
| Age | 1.10 | 1.06-1.14 | < 0.001 | |||
| Male gender | 1.94 | 0.93-4.07 | 0.076 | |||
| Left ventricular ejection fraction | 0.91 | 0.89-0.94 | < 0.001 | |||
| ATRIA risk score | 1.232 | 1.11-1.36 | < 0.001 | |||
| Fasting glucose level | 1.009 | 1.006-1.013 | < 0.001 | 1.006 | 1.004-1.009 | < 0.001 |
| Serum ALT level | 1.022 | 1.001-1.043 | 0.038 | |||
Model 1: risk factors and other factors except CHA2DS2-VASc and ATRIA risk scores. Model 2: variables except risk factors involved in CHA2DS2-VASc and ATRIA risk scores.
CHA2DS2-VASc stands for congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, previous stroke, vascular disease, age 65 to 74 years, and female gender
ALT=alanine aminotransferase; ATRIA=Anticoagulation and Risk Factors in Atrial Fibrillation
Fig. 1Receiver operating characteristics (ROC) curve analysis of risk scores. CHA2DS2-VASc stands for congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, previous stroke, vascular disease, age 65 to 74 years, and female gender. ATRIA=Anticoagulation and Risk Factors in Atrial Fibrillation
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
| Authors' roles & responsibilities | |
|---|---|
| DU | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |